MetaCap

Damora Therapeutics (DMRA) vs Precigen (PGEN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Damora Therapeutics (DMRA) has outperformed Precigen (PGEN) over the past year, gaining 38.5% versus a gain of 8.5%. Over five years, PGEN leads with a +9.1% price change compared with -68.8% for DMRA. Precigen is the larger company by market cap ($1.51 billion vs $1.44 billion), about 1.1 times the size.

On valuation, Damora Therapeutics trades at a lower trailing P/E (13.6x vs 38.3x for Precigen).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DMRA+38.46%PGEN+8.51%
+128%+50%-27%
Nov 21, 20251 yearNov 20, 2026
DMRA-69.04%PGEN+11.97%
+138%+15%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DMRA versus PGEN key metrics
MetricDMRAPGEN
Share price$23.22$4.21
Market cap$1.44B$1.51B
1-day change-4.44%+1.20%
YTD return+0.91%+0.72%
1-year return+38.46%+8.51%
5-year return-68.83%+9.07%
P/E ratio (TTM)13.5838.27
EPS (TTM)$1.71$0.11
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$9.68M
Revenue growth (YoY)—+146.73%
Net income (latest FY)$-209.84M$-250.64M
Operating margin—-1141.13%
Net margin—-2588.21%
52-week high$38.33$8.98
52-week low$15.76$3.04
Distance from 52-week high-39.41%-53.12%
Analyst consensusstrong_buybuy
Avg. price target upside+101.46%+224.70%
Average volume584.28K5.68M
Shares outstanding61.90M358.55M
Employees7160
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • DMRA has outperformed PGEN by 30.0 percentage points over the past year.
  • Precigen trades at a higher earnings multiple (38.3x vs 13.6x trailing P/E).

About Damora Therapeutics

DMRA stock →

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

About Precigen

PGEN stock →

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.

Health Care · Biotechnology: Pharmaceutical Preparations · 160 employees

DMRA vs PGEN FAQ

Which is bigger, Damora Therapeutics or Precigen?

Precigen (PGEN) is larger, with a market capitalization of $1.51B compared with $1.44B for Damora Therapeutics (DMRA).

Which stock has performed better over the past year, DMRA or PGEN?

DMRA returned +38.46% over the past 12 months, compared with +8.51% for PGEN (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, DMRA or PGEN?

DMRA has the lower trailing P/E at 13.6, versus 38.3 for PGEN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are Damora Therapeutics and Precigen in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons